CD274 and non-small cell lung carcinoma: This approval was based on published data from EMPOWER-Lung 1: a phase 3, multicenter, open-label, global randomized-controlled trial comparing cemiplimab monotherapy with investigator’s choice of platinum-doublet chemotherapy for the first-line treatment of patients with advanced NSCLC whose tumors express PD-L1 ≥50% (1).